1. P160 The first phase 2A proof-of-concept study of a selective NLRP3 inflammasome inhibitor, dapansutrile™ (OLT1177™), in acute gout. (March 2019) Authors: Jansen, TL; Klück, V; Janssen, M; Comarniceanu, A; Efdé, M; Scribner, CL; Barrow, RB; Skouras, DB; Dinarello, CA; Joosten, LA Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 1 Page Start: A70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗